ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Cygnal Therapeutics has emerged from stealth mode with $65 million in funding, mostly from the venture capital firm Flagship Pioneering. The Cambridge, Massachusetts–based biotech firm focuses on exoneurobiology, the neurobiology of the peripheral nervous system. CEO Pearl Huang says nerves outside the central nervous system play a significant role in disease and that Cygnal’s multifaceted platform will allow it to find small molecules and build biologics that affect the activity of these nerves.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter